Thiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation

dc.contributor.authorEl-Cheikh, Jean
dc.contributor.authorMassoud, Radwan
dc.contributor.authorMoukalled, Nour M.
dc.contributor.authorHaffar, Basel
dc.contributor.authorAssi, Hazem I.
dc.contributor.authorZahreddine, Ammar
dc.contributor.authorMahfouz, Rami A.R.
dc.contributor.authorBazarbachi, Ali Abdul Hamid
dc.contributor.departmentSpecialized Clinical Programs and Services
dc.contributor.departmentInternal Medicine
dc.contributor.departmentPathology and Laboratory Medicine
dc.contributor.departmentBone Marrow Transplantation (BMT) Program
dc.contributor.departmentDivision of Hematology Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:20:24Z
dc.date.available2025-01-24T12:20:24Z
dc.date.issued2018
dc.description.abstractA study evaluating the optimal dose of myeloablation in thiotepa, busulfan, and fludarabine (TBF) conditioning included 29 patients who received TBF conditioning before allogeneic stem-cell transplantation. Thirteen patients received 5 mg/kg thiotepa; the remaining 16 patients received 10 mg/kg. Patients deemed fit to receive 10 mg/kg conditioning had better overall and progression-free survival than those who received 5 mg/kg, with no additional toxicities. Introduction: The optimal intensity of myeloablation with a reduced-toxicity conditioning regimen to decrease relapse rate after allogeneic stem-cell transplantation without increasing transplant-related mortality (TRM) has not been well established. Materials and Methods: We compared outcomes between 5 mg/kg (T5) and 10 mg/kg (T10) thiotepa-based conditioning regimens in 29 adults who underwent allogeneic stem-cell transplantation for hematologic malignancies. Results: After a median follow-up of 11 months, TRM was 0% and 14% at 100 days and 1 year, respectively, with TRM observed only in the T5 group (P = .016). The relapse incidence at 1 year was 20%. No patient had disease in first complete remission at the time of transplantation. At 1 year, progression-free and overall survival were 30% versus 87% (P = .012) and 46% versus 87% (P = .008) in the T5 and T10 groups, respectively. In univariate and multivariate analysis, only age at transplantation and total dose of thiotepa had a significant impact on TRM, overall, and progression-free survival. Conclusion: Patients deemed fit to receive T10-based conditioning for allogeneic stem-cell transplantation to treat high-risk hematologic malignancies had better overall and progression-free survival than those who received T5 with no additional toxicities. Patients should be stratified before conditioning, and those judged fit should receive T10, while the others should consider alternative reduced-intensity conditioning regimens. © 2018 Elsevier Inc.
dc.identifier.doihttps://doi.org/10.1016/j.clml.2018.02.016
dc.identifier.eid2-s2.0-85044753350
dc.identifier.pmid29625929
dc.identifier.urihttp://hdl.handle.net/10938/34278
dc.language.isoen
dc.publisherElsevier Inc.
dc.relation.ispartofClinical Lymphoma, Myeloma and Leukemia
dc.sourceScopus
dc.subjectDose intensity
dc.subjectHematological malignancies
dc.subjectHigh risk
dc.subjectReduced toxicity conditioning regimens
dc.subjectAdult
dc.subjectDose-response relationship, drug
dc.subjectFemale
dc.subjectHematologic neoplasms
dc.subjectHematopoietic stem cell transplantation
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle aged
dc.subjectMyeloablative agonists
dc.subjectRemission induction
dc.subjectRetrospective studies
dc.subjectSurvival analysis
dc.subjectThiotepa
dc.subjectTransplantation conditioning
dc.subjectTransplantation, homologous
dc.subjectYoung adult
dc.subjectAzacitidine
dc.subjectBusulfan
dc.subjectDasatinib
dc.subjectFludarabine
dc.subjectImatinib
dc.subjectSorafenib
dc.subjectMyeloablative agent
dc.subjectAge
dc.subjectAged
dc.subjectAllogeneic stem cell transplantation
dc.subjectArticle
dc.subjectCancer chemotherapy
dc.subjectCancer survival
dc.subjectChimera
dc.subjectClinical article
dc.subjectDrug dose comparison
dc.subjectEngraftment
dc.subjectHematologic malignancy
dc.subjectHuman
dc.subjectLeukemia relapse
dc.subjectLeukemia remission
dc.subjectMyeloid leukemia
dc.subjectNeutrophil
dc.subjectOutcome assessment
dc.subjectOverall survival
dc.subjectProgression free survival
dc.subjectRetrospective study
dc.subjectSurgical mortality
dc.subjectThrombocyte
dc.subjectTreatment duration
dc.subjectAllotransplantation
dc.subjectComparative study
dc.subjectDose response
dc.subjectHematologic disease
dc.subjectMortality
dc.subjectProcedures
dc.subjectRemission
dc.titleThiotepa 10 mg/kg Treatment Regimen Is Superior to Thiotepa 5 mg/kg in TBF Conditioning in Patients Undergoing Allogeneic Stem-Cell Transplantation
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2018-4248.pdf
Size:
319.85 KB
Format:
Adobe Portable Document Format